13therapeutics is a spin out from the Oregon Health and Science University (OHSU) and has exclusively licensed peptides on a world-wide basis. Two U.S. patents claiming the composition of the lead peptide and its use in all inflammatory conditions involving Toll-Like Receptor (TLR) signaling have been issued, and several additional “use patents” have been filed. The company is capable of performing all in vitro testing in house and subcontracts with OHSU and other academic institutions for animal model testing.
The company is privately funded and has received NIH peer reviewed grants, including multiple Phase II and a Phase III SBIR grant.
13 Therapeutics is led by a seasoned and diverse management team:
Steven H. Hefeneider, Ph.D. serves as the company’s President and CSO. An immunologist with over 30 years of experience and an associate professor at OHSU, he is the co-inventor of the P13 peptide and oversees scientific direction. He was one of the initial scientists at Immunex.
Sharon L. McCoy, M.S. is the Vice President of Product Development and Director of Research. A principal investigator on a number of the company’s SBIR grants, she is also a co-inventor of the P13 peptide. Ms. McCoy oversees all laboratory studies and technical personnel.
Thomas H. Bruggere, M.S., MBA is the founder and former CEO of Mentor Graphics Corp. and serves as the Chairman and CEO of 13therapeutics™. He has served on the boards of both biotech and technology companies and actively oversees all business development.
Supporting this team is a strong network of research collaborators and advisors assembled to advance current and new animal efficacy models and future clinical trials. These members come from credentialed medical research institutions, namely Oregon Health and Science University (OHSU), Indiana University, Oregon State University and the Oregon Clinical and Translational Research Institute (OCTRI).